ProCE Banner Activity

Axicabtagene Ciloleucel in Patients With Refractory Large B-Cell Lymphoma: Extended 2-Yr Follow-up of Phase II ZUMA-1 Trial

Slideset Download
Conference Coverage
In a 2-year follow-up analysis of ZUMA-1, patients with refractory large B-cell lymphoma who received axicabtagene ciloleucel showed durable responses, including patients with high-risk disease.

Released: March 14, 2019

Expiration: March 12, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology